Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
Masahiro Tsuboi(National Cancer Center Hospital East), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Ki Hyeong Lee(Chungbuk National University Hospital), Roy S. Herbst(Smilow Cancer Hospital), Yuri Rukazenkov(Chinese University of Hong Kong), Wu‐Chou Su(National Cheng Kung University Hospital), Jonathan W. Goldman(University of California, Los Angeles), Ana Bolanos(Chinese Academy of Medical Sciences & Peking Union Medical College), Arunee Dechaphunkul(Prince of Songkla University), Margarita Majem(Chinese Academy of Medical Sciences & Peking Union Medical College), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Frances A. Shepherd(University Health Network), Thomas John(Austin Hospital), Terufumi Kato(Taipei Veterans General Hospital), Nhieu Thi Le(Chinese Academy of Medical Sciences & Peking Union Medical College), Lynne Poole(AstraZeneca (United Kingdom)), Christian Grohé(DRK Kliniken Berlin), Filippo de Marinis(Carlo Forlanini Hospital), Jie Wang(Shanghai Ocean University), Shun Lü(Shanghai Jiao Tong University)
Cited by 605
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k